ACCP Should Not Fear DTC Genetic-Testing Advertising

Many physicians support the use of the DTC drug ads that ACCP implies threaten patient care, when in fact those ads are running with a near-perfect record even before FDA has had a chance to review them.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

save

save